Connor, Clark & Lunn Investment Management Ltd.

Position in CRVS — Corvus Pharmaceuticals, Inc.

CIK 1596800 VANCOUVER, A1

Position in CRVS

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,253,185

+$2,025,626 QoQ

Shares Held

217,750

+159.5% QoQ

Ownership

0.259%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#45

of 172 holders

Holding Since

Mar 2020

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. CRVS ranks #39 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,253,185	217,750	+159.5%	Shares	Sole	2026-08-13
2026-03-31	$1,227,559	83,907	+198.4%	Shares	Sole	2026-05-11
2025-12-31	$216,500	28,117	-79.5%	Shares	Sole	2026-02-10
2024-09-30	$723,523	137,031	+64.7%	Shares	Sole	2024-11-08
2024-06-30	$151,464	83,222	-5.4%	Shares	Sole	2024-08-09
2024-03-31	$156,654	88,008	+23.6%	Shares	Sole	2024-05-09
2023-12-31	$125,326	71,208	+0.5%	Shares	Sole	2024-02-09
2023-09-30	$103,489	70,883	-16.0%	Shares	Sole	2023-11-13
2023-06-30	$193,202	84,368	-0.6%	Shares	Sole	2023-08-10
2020-06-30	$230,976	84,918	-0.8%	Shares	Sole	2020-08-13
2020-03-31	$180,624	85,604	—	Shares	Sole	2020-05-13
No filing history on record for this holder in this stock.